Engineering and biological characterization of VB6-845, an Anti-EpCAM immunotoxin containing a t-cell epitope-depleted variant of the plant toxin bouganin

Journal of Immunotherapy

Volumn 32, Issue 6, 2009, Pages 574-584

  Cizeau, Jeannick ^a   Grenkow, Danielle M ^a   Brown, Jennifer G ^a   Entwistle, Joycelyn ^a   MacDonald, Glen C ^a,b  

^a Viventia Biotech Inc   (Canada)

^b NONE   (Canada)

Author keywords

Bouganin; EpCAM; Fab; Immunotoxin; T cell epitope

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN SULFATE; CARBOXY TERMINAL TELOPEPTIDE; CHLORAMBUCIL; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DE BOUGANIN; DENILEUKIN DIFTITOX; DOCETAXEL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; EPITOPE; ETOPOSIDE; FLUOROURACIL; FURIN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; IMMUNOTOXIN 4D5 MOCB ETA; IMMUNOTOXIN VB6 845; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PLANT TOXIN; RIBOSOME INACTIVATING PROTEIN 1; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VB6 845; VINCRISTINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BOLUS INJECTION; BOUGAINVILLEA SPECTABILIS; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; GENETIC ENGINEERING; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; LIGHT CHAIN; MAINTENANCE DRUG DOSE; MOUSE; NONHUMAN; PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; SCID MOUSE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION MOLECULES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTOXINS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASMS; NYCTAGINACEAE; PLANT PROTEINS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651163873     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a6981c     Document Type: Article

References (51)

1. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res. 2001;81:93-124.
2. Fracasso G, Bellisola G, Castelletti D, et al. Immunotoxins and other conjugates: preparation and general characteristics. Mini Rev Med Chem. 2004;4:545-561.
3. Sandvig K, van Deurs B. Membrane traffic exploited by protein toxins. Annu Rev Cell Dev Biol. 2002;18:1-24.
4. Fabbri A, Travaglione S, Falzano L, et al. Bacterial protein toxins: current and potential clinical use. Curr Med Chem. 2008;15:1116-1125.
5. Stirpe F, Batelli MG. Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci. 2006;63:1850-1866.
6. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998;58:968-975.
7. Yamaizumi M, Chen H, Vlahov IR, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15:245-250.
8. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem. 1987;262:8707-8711.
9. Phan LD, Perentesis JP, Bodley JW. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem. 1993;268:8665-8668.
10. Barbieri L, Batelli MG, Stirpe F. Ribosome-inactivating proteins from plants. Biochim Biophys Acta. 1993;1154: 237-282.
11. Bolognesi A, Barbieri L, Abbondanza A, et al. Purification and properties of new ribosome-inactivating proteins with RNA N-glycosidase activity. Biochim Biophys Acta. 1990;1087: 293-302.
12. Bolognesi A, Barbieri L, Carnicelli D, et al. Purification and properties of a new ribosome-inactivating protein with RNA N-glycosidase activity suitable for immunotoxin preparation from the seeds of Momordica cochinchinensis. Biochim Biophys Acta. 1989;993:287-292.
13. Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem. 1987;262:5908-5912.
14. Bolognesi A, Polito L, Olivieri F et al. New ribosomeinactivating proteins with polynucleotide:adenosine glycosidase and antiviral activities from Basella rubra L. And Bougainvillea spectabilis Willd. Planta. 1997;203:422-429.
15. Den Hartog MT, Lubelli C, Boon L, et al. Cloning and expression of cDNA coding for bouganin, a type-I ribosomeinactivating protein from Bougainvillea spectabilis Willd. Eur J Biochem. 2002;269:1772-1779.
16. Bolognesi A, Polito L, Tazzari PL, et al. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol. 2000; 110:351-361.
17. Bolognesi A, Polito L. Immunotoxins and other conjugates: Pre-clinical studies. Mini Rev Med Chem. 2004;4:563-583.
18. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J. 2006;8:E532-E551.
19. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221-237.
20. Momburg F, Moldenhauer G, Hämmerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987;47:2883-2891.
21. Ogura E, Senzaki H, Yoshizawa K, et al. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res. 1998;18:3669-3675.
22. Xie X, Wang CY, Cao YX, et al. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol. 2005;11:344-347.
23. Goel S, Bauer RJ, Desai K, et al. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Ann Oncol. 2007; 18:1704-1707.
24. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005;92:342-349.
25. MacDonald GC, Glover N. Effective tumor targeting: strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel. 2005;8:177-183.
26. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 1999;59:5758-5767.
27. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9:2837-2848.
28. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Design, Development and Therapy. 2008;2:105-114.
29. Biggers K, Scheinfeld N. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. Curr Opin Mol Ther. 2008;10:176-186.
30. Lei SP, Lin HC, Wang SS, et al. Characterization of the Erwinia carotovora pelB gene and its product pectate lyase. J Bacteriol. 1987;169:4379-4383.
31. Goyal A, Batra JK. Inclusion of a furin-sensitive linker spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem J. 2000; 345:247-254.
32. Johnston S, Lee JH, Ray DS. High-level expression of M13 gene II protein from an inducible polycistronic messenger RNA. Gene. 1985;34:137-145.
33. Benedict CA, MacKrell AJ, Anderson WF. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods. 1997;201:223-231.
34. Saleh MN, Stapleton JD, Khazaeli MB, et al. Generation of a human anti-idiotypic antibody that mimics GD2 antigen. J Immunol. 1993;151:3390-3398.
35. Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel. 2007;10:219-227.
36. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene gycol of recombinant immunotoxin anti-Tac(Fv)-P38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA. 2000;97:8548-8553.
37. Filpula D, Yang K, Basu A, et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem. 2007;18:773-784.
38. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated from of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol. 2006; 177:8822-8834.
39. Laroche Y, Heymans S, Capaert S, et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood. 2000; 96:1425-1432.
40. Onda M, Beers R, Xiang L, et al. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA. 2008;105: 11311-11316.
41. Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science. 1992; 256:1817-1820.
42. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28:482-490.
43. Tangri S, Mothé BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005;174:3187-3196.
44. Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med. 2008;14:450-460.
45. Maetzel D, Denzel S, Mack B, et al.Nuclear signaling by tumorassociated antigen EpCAM. Nat Cell Biol. 2009;11:162-171.
46. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96:417-423.
47. O'Hare M, Brown AN, Hussain K, et al. Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS. 1990; 273:200-204.
48. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994;269: 18167-18176.
49. Inocencio NM, Moehring JM, Moehring TJ. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem. 1994;269:31831-31835.
50. Rosenblum MG, Cheung LH, Liu Y, et al. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res. 2003;63:3995-4002.
51. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 2001;61:4750-4755.